Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BECTON-DICKINSON LAUNCHING FACSCOUNT CD4 T LYMPHOCYTE COUNTER

This article was originally published in The Gray Sheet

Executive Summary

BECTON-DICKINSON LAUNCHING FACSCOUNT CD4 T LYMPHOCYTE COUNTER in the U.S. at a list price of $34,975. The company began taking orders for the device following its 510(k) clearance by FDA on Sept. 19. FACSCount, which provides absolute counts of CD4, CD8 and CD3 T lymphocytes, is intended for use in monitoring the status of HIV-positive patients; BD notes that the CD4 cells are the "cellular parameter most closely associated with HIV disease progression and therapy decisions."
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002835

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel